GMAB · Genmab A/S

Track GMAB — free

$35.68 +0.11 (+0.30%) At close · Sep 30

Rebalance outlook locked

Market Cap

$21.72B

614.90M

Volume · Sep 30 5.15M Avg daily vol (3M) 2.39M

Up next

Next earnings call

Oct 30, 2026 Est · unconfirmed · in 4 wks

Q1 2026 earnings call transcript

call held May 7, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$4.13B

Trailing 12 months

Net income (TTM)

$788.00M

Trailing 12 months

Revenue growth YoY

+24.9%

Year over year

Operating margin

26.0%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

4.0%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

+21.3%

Trailing year

Short interest

0.8%

Latest settlement · 3.2 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Limited Quant / Vol Moderate

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +21%

above

Price vs 50-day avg +10%

above

RSI (14) 68

neutral

MACD trend Positive

52-week position 100%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +7%

trailing

6-month return +26%

trailing

YTD return +16%

this year

Relative strength +14%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $32 › 200d $30 — 50d above 200d

Institutional flow Accumulating

+5% holders QoQ · +48 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.80% of float · ▼ -28.0% MoM · 3.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

293 holders — near 3-yr high, broad support

Squeeze score 40

elevated · 0–100

Fundamentals

Limited

Not enough data for a confident read.

Quant / Vol

risk profile

Moderate

Volatility 33%

annualized · 1-yr

Max drawdown −33%

past year

ATR 2.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed May 7, 2026

Operating expenses · 2026 $2.7B – $2.9B

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+21% Bullish

Price vs 50-day avg

+10% Bullish

RSI (14)

68 Neutral

MACD trend

Positive Bullish

52-week position

100% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $32 › 200d $30 — 50d above 200d

Institutional flow Accumulating

+5% holders QoQ · +48 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

0.80% of float · ▼ -28.0% MoM · 3.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

293 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $24 Now $36 · 100% Range high $36

vs 200-day avg +21% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
GMAB Genmab A/S this stock	$21.72B	+15.8%	—	—	0.8%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+15.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-1.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+553.0%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

293

% held: 17.4%
Net QoQ: +24.9M sh
Top holder: Paradigm Biocapital Advis…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

4.9M

Days to cover: 3.2d
Change: -1.9M sh

View

Short Volume

Short vol %

73%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

5.0K

Value: $166.2K
As of: Sep 9, 2026

View

Off-Exchange

Off-exchange %

41.7%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Daniel Goldman

Amount: $50.0K–$100.0K
Traded: Jul 10, 2023

View

Filings

SEC Filings

Latest

6-K

Filed: Sep 29, 2026
This year: 50

View

Proposed Sales

Value

$67.2K

Shares: 1.3K
Filed: Jun 17, 2025

View

Earnings & Events

Earnings Calls

Last call

Sep 22, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
GMAB	+2.7%	+7.2%	+26.2%	+7.6%	+15.8%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	+3.3%	+7.1%	+14.0%	+8.2%	+4.0%

Key facts CIK 1434265 CUSIP 372303206 13F (30d) 7 filings 7 filers Visit website Investor relations

GMAB · Genmab A/S

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Versus peers

At a glance

Performance